
    
      Multicentric study, open, single arm, designed to evaluate the efficacy(response rate and
      response duration) and security of a sequential scheme of treatment with Bortezomib in
      combination with Melfalan and Prednisone (V-MP) (patients > 75 years) or Bortezomib and
      Adriamycine in combination with Melfalan and Prednisone (VAMP) (patients <= 75 years) follow
      by Thalidomide in combination with Cyclophosphamide and Dexamethasone (TaCyDex) in patients
      with refractary or relapse multiple myeloma.
    
  